Biotech Centrexion Therapeutics set terms for its planned initial public offering on Monday, saying in a regulatory filing that it plans to offer 5 million shares priced at $14 to $16 each. The company would raise $75 million at the midpoint of that range. Centrexion, which specializes in non-opioid pain treatments, is planning to list on Nasdaq under the ticker symbol “CNTX”. BofA Merrill Lynch, Leerink and Evercore are joint underwriters on the deal.
Have breaking news sent to your inbox. Subscribe to MarketWatch’s free Bulletin emails. Sign up here.